In the last 3 decades, our improved knowledge of heart failure etiology has been the catalyst for major advances in its medical management. This session will help you to understand the modern pharmacologic treatment of patients with this syndrome and offer a peek into advances that can be expected in the coming years. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 2/8/2020, and they are subject to change as new information is published.
A disease state educational presentation reviewing the epidemiology and clinical course of heart failure, including the identification of signs and symptoms of worsening heart failure. The presentation discusses management of heart failure care surrounding hospitalization, and the interplay between optimizing heart failure care and quality and performance measures. Dr. Desai shares some practical insights to optimizing heart failure management and delivering value-based care.
In this episodes, we will discuss a systematic review and meta-analysis that examines outcomes from the use of furosemide compared to torsemide in patients with congestive heart failure.
Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF reduction in patients with T2D and established CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.
This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.
Join us as we examine the risk of hospitalization for heart failure (HF) among patients with type 2 diabetes (T2D) and explore evidence-based risk reduction strategies that you can incorporate into your practice. We will discuss the results of the DECLARE trial, the largest cardiovascular (CV) outcomes trial to study hospitalization for HF reduction in patients with T2D and established CV disease or multiple CV risk factors. We'll also discuss the results of the landmark DAPA-HF trial that support FARXIGA being the FIRST and ONLY FDA-approved sodium-glucose cotransporter 2 inhibitor (SGLT2) for patients with HF with reduced ejection fraction (HFrEF) with and without T2D.
This program will highlight a different approach to the treatment of heart failure with reduced ejection fraction (HFrEF). By targeting a mechanism of action aligned to pathophysiologic pathways, it is possible to reduce patient mortality and morbidity, while providing a proven safety and tolerability profile to help provide confidence in selecting your first-choice therapy for patients with HFrEF.
Heart failure (HF) affects more than 6 million Americans with approximately 50% mortality at 5 years. This session will show how recent advances in heart failure treatment have contributed to improved survival. This session will also discuss the guidelines, supporting evidence, and interventions to maximize hypertension management for individual patients. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 9/10/2020, and they are subject to change as new information is published.